Lexology June 29, 2020
Against the backdrop of the world coming to terms with the aftermath of the COVID-19 pandemic and adapting to the paradigm of the “new normal,” in this series of articles we aim to explore and prepare you for what is to come in the areas of mergers and acquisitions and investments into the healthcare and life sciences industry.
The healthcare and life sciences industry has traditionally been quite robust in terms of supply and demand (driven by, among other factors, a growing aging population, the increasing prevalence of chronic diseases, the innovations and advancements in medical technology, and the expansion of health care systems in developing markets) and consequently we saw a steady number of deal flows in this sector...
Today's Sponsors
Today's Sponsor